dc.contributor.author |
David, L. |
|
dc.contributor.author |
Ghicavîi, V. |
|
dc.contributor.author |
Butorov, I. |
|
dc.contributor.author |
Stolear, A. |
|
dc.contributor.author |
Butorov, V. |
|
dc.contributor.author |
Necula, Gh. |
|
dc.date.accessioned |
2020-03-25T22:46:27Z |
|
dc.date.available |
2020-03-25T22:46:27Z |
|
dc.date.issued |
2010 |
|
dc.identifier.citation |
DAVID, L., GHICAVÎI, V., BUTOROV, I., STOLEAR, A., BUTOROV, V., NECULA, Gh. Aspecte clinico-farmacologice ale heptralului în tratamentul steatohepatitei non-alcoolice. In: Curierul Medical. 2010, nr. 3(315), pp. 98-104. ISSN 1875-0666. |
en_US |
dc.identifier.issn |
1875-0666 |
|
dc.identifier.uri |
http://moldmedjournal.md/wp-content/uploads/2016/09/7.pdf |
|
dc.identifier.uri |
http://repository.usmf.md/handle/20.500.12710/8102 |
|
dc.description |
Catedra Farmacologie şi farmacologie clinică, Catedra Medicină internă nr. 6, Catedra Medicină internă nr. 1, USMF „Nicolae Testemiţanu”, Conferinţa Ştiinţifico-Practică „Medicina modernă, actualităţi şi perspective”, consacrată aniversării de 40 de ani ai Spitalului Clinic al Ministerului Sănătăţii, 27-28 mai, 2010, Chişinău, Republica Moldova |
en_US |
dc.description.abstract |
The study included 50 patients with NASH. Among them were 15 men and 35 women. Initially all patients had abdominal type obesity.
Overweight body mass was diagnosed in 5 patients, 5 – I degree obesity, 8 – II degree, 7 – degree III and IV. Heptral is a pharmaceutical
preparation with positive influence on the main pathogenetic links of steatohepatitis. Including Heptral in the complex therapy of patients with
non-alcoholic steatohepatitis decreased the activity of enzymes of cytolysis, significantly improved the lipid peroxidation and hormonal status
indices in comparison with the basic therapy. Heptral also improved patients’ quality of life. |
en_US |
dc.description.abstract |
В исследование были включены 50 пациентов (15 мужчин и 35 женщин) с НАСГ. Первоначально все пациенты имели ожирение
брюшного типа. Избыточная масса тела была диагностирована у 5 пациентов: у 5 – I-й, у 8 – II-й, 7 – III-й и IV-й степени ожирения.
Включение гептрала в комплексную терапию больных нелкогольным стеатогепатитом позволило значительно уменьшить активность
ферментов цитолиза, улучшить показатели перекисного окисления липидов и гормонального статуса. |
|
dc.language.iso |
ro |
en_US |
dc.publisher |
Ministerul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” |
en_US |
dc.relation.ispartof |
Curierul Medical: Conferinţa Ştiinţifico-Practică „Medicina modernă, actualităţi şi perspective”, consacrată aniversării de 40 de ani ai Spitalului Clinic al Ministerului Sănătăţii, 27-28 mai, 2010, Chişinău, Republica Moldova |
|
dc.subject |
heptral |
en_US |
dc.subject |
non-alcoholic steatohepatitis |
en_US |
dc.title |
Aspecte clinico-farmacologice ale heptralului în tratamentul steatohepatitei non-alcoolice |
en_US |
dc.title.alternative |
Clinical and pharmacological aspects of heptral in the treatment of non-alcoholic steatohepatitis |
en_US |
dc.title.alternative |
Клинико-фармакологические аспекты гептрала в лечении неалкогольного стеатогепатита |
en_US |
dc.type |
Article |
en_US |